March 09, 2026

MDA Conference 2026: Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy

Evry, France (March 9, 2026) –  Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the MDA (Muscular Dystrophy Association) Conference 2026 the first […]

Read more

MDA Conférence 2026 : Atamyo Therapeutics présente des résultats prometteurs chez les premiers patients traités avec sa thérapie génique ATA-200 dans l’essai clinique ciblant la myopathie des ceintures LGMD-R5

Evry, France (9 mars 2026) –  Atamyo Therapeutics, société de biotechnologie spécialisée dans le développement de thérapies géniques de nouvelle génération pour les dystrophies musculaires des ceintures (limb-girdle muscular dystrophy, LGMD), a dévoilé lors de […]

Read more

February 16, 2026

Atamyo Therapeutics Announces the Dosing of a Fourth Patient with ATA-200 in an Ongoing LGMD-R5 Clinical Trial, Supported by CureSCG

Atamyo Therapeutics announces continued progress in its ongoing clinical trial of ATA-200, with the recent dosing of a fourth patient, marking an important milestone in the development of its gene therapy for γ-sarcoglycan related limb […]

Read more

February 03, 2026

Atamyo Therapeutics Announces First Three Patients Dosed with ATA-200 Gene Therapy in on-going LGMD-R5 Clinical Trial, and Extension of Partnership with the Dion Foundation

Evry, France and Boston, MA (February 3, 2026) – Atamyo Therapeutics and The Dion Foundation for Children with Rare Diseases, today announced the expansion of their partnership to support financing of the first-in-human clinical trial […]

Read more